Alpine Immune Sciences

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Alpine Immune Sciences advances drug pipeline amidst financial challenges

Alpine Immune Sciences shows promise with progress on povetacicept and strategic studies for autoimmune diseases.
While facing financial challenges, the company's strong cash position and collaborations offer growth opportunities.
Effective cost management, successful clinical trials, and market expansion are crucial for Alpine's future success.

Alpine Immune Sciences reports robust 2023 performance and clinical advancements

Alpine Immune Sciences demonstrated strong financial performance and promising clinical advancements in 2023.
The company's focus on povetacicept as a disease-modifying therapy presents significant opportunities for growth.
Challenges lie in maintaining clinical momentum and managing expenses effectively to sustain progress.
Overall, Alpine's strategic initiatives position it well for continued success in the biopharmaceutical space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alpine Immune Sciences is a clinical-stage biopharmaceutical business focused on researching and developing protein-based immunotherapies to treat autoimmune and inflammatory disorders. Its strategy incorporates a patented scientific platform for transforming native immune system proteins into differentiated, multi-targeted therapies. ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Evotec SE

HAMBURG, Germany & SEATTLE--(BUSINESS WIRE)--Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today announced that Evotec's Seattle-based subsidiary, Just – Evotec Biologics, Inc., expanded a multi-year partnership with Alpine for the development of a commercial process for ALPN-303, an engineered TACI domain with significantly improved potency against the B cell cytokines BAFF and APRIL, being developed for

Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10th, 2022, at 4:05 p.m. ET/1:05 p.m. PT. A live webcast of the fireside chat will be available online in the investor relations section of th

Alpine Immune Sciences Announces Participation in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the appointment of Jörn Drappa, MD, PhD, to its Board of Directors. “We are very pleased to welcome Dr. Drappa to our Board of Directors. Jörn brings a tremendous depth of experience leading the successful development of immunology drugs across both small biotech and l

Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the appointment of industry veteran Andrew S. Sandler, M.D., as its Chief Medical Officer. Dr. Sandler joins Alpine from Kiadis Pharma, a Sanofi Company, where he was Chief Medical Officer. Dr. Sandler's anticipated start date is August 17, 2022. “We are very excited a

Alpine Immune Sciences Appoints Andrew S. Sandler, M.D.

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the presentation of novel preclinical and clinical data in a poster titled “ALPN-303, an Engineered Dual BAFF/APRIL Antagonist, Potently Inhibits Pathogenic Autoantibodies in Preclinical Models, with Corresponding Pharmacodynamic Activity in Humans,” at the European Al

Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the acceptance of abstracts for presentation at the 2022 European Congress of Rheumatology (EULAR) Annual Congress in Copenhagen, Denmark to be held June 1–4, 2022 and the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago to be held June 3-7,

Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold placed on its NEON-2 trial evaluating davoceticept (ALPN-202), a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor, in combination with pembrolizumab in adu

Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -47.06% and 2.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Tops Revenue Estimates

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. “Our clinical pipeline of novel autoimmune and immuno-oncology candidates continues to make significant progress, as highlighted by the promising monotherapy dose escalation d

Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will participate at the following investor conferences in May 2022: LifeSci Partners Immunology & Inflammation Symposium Date: Tuesday, May 10, 2022 Time: 3:00 p.m. ET/12:00 p.m. PT Event: Fireside Chat BofA Securities Healthcar

Alpine Immune Sciences Announces Participation in May Investor Conferences

Implementing an appropriate strategy would capture the most profits. One such strategy is diversification. A promising stock for your portfolio to diversify is Alpine Immune Science. As a rising leader in immuno-oncology, Alpine has great medicines and has thus been able to secure three interesting partnerships.

Alpine: Rest Before Rallying Again

Alpine Immune Sciences Inc (NASDAQ: ALPN) announced the oral presentation of results from the dose-escalation portion of NEON-1 study of davoceticept monotherapy in advanced malignancies. The data were shared at the 2022 Annual Meeting of the American Association for Cancer Research.

Alpine Immune's Davoceticept Monotherapy Reduces Tumors In Early Stage Study

NEW ORLEANS--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the oral presentation of results from the dose-escalation portion of NEON-1 (NCT04186637), a first-in-human, dose-escalation and expansion study of davoceticept monotherapy in participants with advanced malignancies, at the 2022 Annual Meeting of the American Assoc

AACR 2022: Davoceticept (ALPN-202) Monotherapy Reduces Tumors, Supports Multiple Expansion Cohorts

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a company presentation at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13th, 2022, at 1:30 p.m. ET/10:30 a.m. PT. Alpine will host a virtual investor event on April 12th, 2022, at 6:30 p.m. ET, to coincide w

Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced a publication in Nature Communications on the preclinical development of davoceticept, Alpine's lead immuno-oncology therapeutic candidate uniquely designed to combine PD-L1-dependent CD28 costimulation with dual PD-L1 and CTLA-4 checkpoint inhibition. CD28 is a criti

Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that Alpine will host a virtual investor event on April 12th, 2022 at 6:00pm ET, to coincide with the 2022 American Association for Cancer Research (AACR) Annual Meeting. During the investor event, Alpine will provide a corporate update on the development strategy for

Alpine Immune Sciences to Host Virtual Investor Event at 2022 AACR Annual Meeting

Alpine Immune Sciences, Inc. (ALPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Alpine Immune Sciences, Inc. (ALPN) Soars 6%: Is Further Upside Left in the Stock?

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -100% and 45.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Misses Revenue Estimates

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2021. “2021 was a period of significant growth at Alpine with the advancement of all three of our clinical programs into significant stages of development,” said Mitche

Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Alpine Immune Sciences, Inc. (ALPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alpine Immune Sciences, Inc. (ALPN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the acceptance of an abstract for presentation at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans to be held April 8–13, 2022. Results from the dose escalation portion of NEON-1, a Phase 1 clinical trial of davoceticept (ALPN-202) as

Alpine Immune Sciences Announces Oral Presentation at the 2022 AACR Annual Meeting

The FDA places a partial clinical hold on Alpine's (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck's Keytruda for treating advanced malignancies. Shares fall.

Alpine (ALPN) Down on FDA Partial Clinical Hold on Cancer Study

The FDA has placed a partial clinical hold on Alpine Immune Sciences Inc's (NASDAQ: ALPN) NEON-2 trial evaluating davoceticept (ALPN-202) in combination with pembrolizumab in adults with advanced malignancies. The partial clinical hold was prompted by Alpine's report of.

Why Alpine Immune's Shares Are Falling Today

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its NEON-2 trial evaluating davoceticept (ALPN-202) in combination with pembrolizumab in adults with advanced malignancies. The partial clinical hold was prompted by Alpine's report

Alpine Immune Sciences Reports FDA Partial Clinical Hold on NEON-2 Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced that members of its management team will participate at the following investor conferences in March 2022: Cowen's 42nd Annual Health Care Conference Date: Monday, March 7, 2022 Time: 2:50 p.m. ET/11:50 a.m. PT Event: Fireside Chat Oppenheimer 32nd Annual Healthcare Co

News for Alpine Immune Sciences Stock (ALPN)